Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. reports company developments as a clinical-stage biotechnology company advancing adeno-associated virus, or AAV, gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
Recurring updates cover TSHA-102 clinical and preclinical data, FDA regulatory interactions and designations, manufacturing and comparability topics, financial results, corporate updates, and employee inducement equity grants under Nasdaq listing rules. Company communications also describe the program’s MECP2 construct design, miRARE technology, and clinical trial activity in Rett syndrome.
Taysha Gene Therapies (Nasdaq: TSHA), a clinical-stage biotech company developing AAV-based gene therapies for CNS diseases, has granted stock options to two new employees. The Compensation Committee approved options to purchase 30,000 shares of common stock at an exercise price of $2.34 per share under the company's 2023 Inducement Plan.
The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Taysha Gene Therapies (NASDAQ: TSHA) has announced the pricing of a public offering, consisting of 46,868,687 shares of common stock at $2.75 per share and pre-funded warrants to purchase 25,858,586 shares at $2.749 per warrant. The company expects to raise approximately $200.0 million in gross proceeds before deducting expenses.
The underwriters have a 30-day option to purchase up to an additional 10,909,090 shares. The offering, led by joint book-running managers Jefferies, BofA Securities, Piper Sandler, and Barclays, is expected to close around May 30, 2025. Taysha is a clinical-stage biotechnology company developing AAV-based gene therapies for severe CNS monogenic diseases.
Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has announced a new public offering of common stock and pre-funded warrants. The offering includes an option for underwriters to purchase up to an additional 15% of shares within 30 days. Jefferies, BofA Securities, Piper Sandler, and Barclays are serving as joint book-running managers for the offering.
The offering will be conducted under a shelf registration statement that was filed with the SEC on December 13, 2024, and became effective on December 20, 2024. The final size, terms, and completion of the offering will depend on market conditions.
The pivotal Part B trial will be a single-arm, open-label study (N=15) in patients ≥6 years old. Remarkably, Part A results showed 100% of patients (N=10) gained/regained ≥1 developmental milestone post-treatment, with the high dose showing superior results compared to low dose.
The treatment has been well-tolerated with no treatment-related serious adverse events. The company plans to submit the pivotal trial protocol this quarter and initiate the trial in Q3 2025. The trial's primary endpoint will assess developmental milestone gain/regain, with patients serving as their own control.
Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has scheduled its Q1 2025 financial results release and corporate update for May 15, 2025, at 8:30 AM ET. The company will host a conference call and webcast accessible via toll-free and international dial-in numbers, with a dedicated conference ID. Investors and interested parties can also access the webcast through Taysha's investor relations website.
Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has announced new stock option grants. The Compensation Committee approved options for 822,000 shares to five new employees on April 1, 2025, under the company's 2023 Inducement Plan.
The options were granted at an exercise price of $1.265, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.